Adductor Spasmodic Dysphonia: Symptoms & Treatment

Adductor spasmodic dysphonia is a neurological voice disorder in which involuntary spasms of the vocal fold muscles cause the voice to sound strained, strangled, or choked during speech. It typically strikes between the ages of 30 and 50, and the hallmark symptom is sudden voice breaks mid-word that make connected speech effortful and unpredictable. The standard treatment is periodic injection of botulinum toxin into the affected laryngeal muscles, though surgical and emerging drug options exist for people who want longer-lasting relief. Despite being recognized for over a century, adductor spasmodic dysphonia remains frequently misdiagnosed, and most patients wait years before getting an accurate name for what is happening to their voice.

What Adductor Spasmodic Dysphonia Sounds and Feels Like

The defining feature of adductor spasmodic dysphonia (ADSD) is involuntary, irregular squeezing of the vocal folds during voicing. Because the vocal folds press together too tightly at unpredictable moments, the voice cuts out or sounds like it is being wrung through a tight space. These breaks tend to be worst on vowel-initial words and during connected speech that requires sustained voicing. A sentence loaded with voiced consonants and vowels will sound dramatically worse than one full of voiceless sounds like “p,” “t,” or “s.” In clinical testing, the difference in severity between all-voiced sentences and voiceless-consonant sentences is so pronounced that it serves as a diagnostic marker, though its sensitivity is limited.¹

One of the more puzzling aspects of this disorder is that the spasms target learned vocal behaviors while largely sparing innate ones. Laughing, crying, yelling, whispering, and yawning tend to come out normally. Research has confirmed that effort ratings for these reflexive vocal behaviors fall well within normal ranges across patients with spasmodic dysphonia, while effort during regular speech is dramatically elevated.² This dissociation is why ADSD can be so socially confusing: someone with a severely disrupted speaking voice may laugh or sing with surprising ease, leading others to wonder whether the problem is “real.” It is. The brain circuits governing reflexive vocalizations simply operate through different pathways than those governing speech.

Vocal Tremor and Related Symptoms

ADSD rarely arrives alone. Roughly a quarter of patients also have vocal tremor, a rhythmic wavering of pitch or loudness that sits on top of the spasmodic breaks. Another fifth have tremor in non-vocal areas, such as the hands or head. A case-control study found patients with spasmodic dysphonia were about three times more likely to have co-occurring tremor than the general population.³ The overlap matters clinically because vocal tremor and ADSD can look alike on examination and are sometimes confused with each other. High-speed video recordings of the vocal folds show that the vibratory patterns of these two conditions frequently coexist in the same patient, complicating both diagnosis and rating of severity.⁴

Despite this high rate of overlap, only about a third of patients with spasmodic dysphonia had ever been evaluated by a neurologist for dystonia or tremor in the case-control study.³ That gap suggests many patients are being managed solely as a “voice problem” without the broader neurological workup that their symptoms warrant.

Why It Takes So Long to Get Diagnosed

On average, patients wait over four years after first seeing a physician for voice symptoms before receiving a diagnosis of spasmodic dysphonia, cycling through nearly four different clinicians in the process.⁵ During that odyssey, many are prescribed medications that do not address the underlying disorder. About 16 percent receive anti-anxiety drugs, and roughly 9 percent get acid reflux medication, reflecting common misattributions of the voice symptoms to psychological stress or gastroesophageal reflux.⁵

The biggest diagnostic challenge is distinguishing ADSD from muscle tension dysphonia (MTD), a voice disorder caused by excessive muscular effort without the neurological underpinning. Both conditions can produce a strained, effortful voice. No single test reliably separates them, but several features raise suspicion of ADSD over MTD: voice breaks that come and go depending on the phonatory task, voice quality that worsens during voiced sentences but improves during voiceless ones, and tiny irregular motion patterns in the vocal folds visible on high-speed imaging.⁶ High-speed digital imaging has identified “micromotions” in ADSD patients that are absent in MTD, and motion irregularity specifically has emerged as a significant predictor of ADSD.⁷

Laryngoscopy, the standard scope-down-the-throat examination, plays a crucial role not so much in confirming ADSD directly but in ruling out other structural problems and identifying co-existing vocal tremor.⁸ Diagnosis typically relies on a combination of perceptual voice evaluation, visualization of the vocal folds, and the clinical judgment of a laryngologist or voice-specialized speech-language pathologist.

What Causes It

ADSD is now understood as a focal dystonia, a disorder of brain circuitry rather than a problem with the vocal folds themselves. For about a century after its first description in 1871, the condition was wrongly attributed to psychological causes. That misconception was not debunked until researchers demonstrated in the late 1960s that patients with spasmodic dysphonia had no higher rate of psychiatric disorders or psychological maladjustment than the general population.⁹

Modern brain imaging shows widespread changes in the network connecting the cerebellum, basal ganglia, thalamus, and cortex in patients with spasmodic dysphonia, with the basal ganglia network playing a particularly central role.¹⁰ This is not a single gene disorder for most patients. Genetic screening of ADSD patients has generally come up empty for the major known dystonia-causing mutations, though rare variants in the THAP1 gene have been identified in individual cases, particularly those with early-onset generalized dystonia that includes laryngeal involvement.¹¹¹² Research into polygenic risk has found that cumulative genetic variation across many genes involved in synaptic function and neuronal development correlates with the abnormal brain connectivity patterns seen in spasmodic dysphonia patients.¹³

Large cohort studies have identified risk factors including a family history of neurological disorders such as dystonia and tremor, recent viral illness, and heavy voice use.¹⁴ Among patients who experienced a sudden onset of symptoms, stress was the most commonly perceived trigger (about 42 percent of the time), followed by upper respiratory infection (about 33 percent) and pregnancy or childbirth (about 10 percent).¹⁵ None of these triggers is rare in daily life, which is why the current thinking is that ADSD arises from a complex interaction between genetic susceptibility and environmental stressors, rather than from any single cause.

Botulinum Toxin Injections

The first-line treatment for ADSD is injection of botulinum toxin (commonly referred to by the brand name Botox) directly into the overactive vocal fold muscles. A double-blind, placebo-controlled trial established decades ago that botulinum toxin type A markedly reduces vocal perturbation and produces significant subjective voice improvement compared to placebo.¹⁶ The treatment works by temporarily weakening the muscles that are squeezing too hard, which reduces the voice breaks and strain.

Bilateral injections, targeting both vocal folds, improve voice outcomes and quality of life, with the beneficial effect typically lasting around 15 to 18 weeks before the spasms gradually return.¹⁷ Most patients settle into a cycle of injections roughly every three to four months, though the interval varies. Longitudinal data spanning hundreds of treatments show that average voice handicap improves by about 10 percent and perceptual voice quality improves by about 30 percent across injection cycles.¹⁸

The drawback is that the treatment overshoots before it settles. Roughly half of all treatments produce a period of breathiness in the days to weeks after injection, and difficulty swallowing liquids occurs after about 14 percent of treatments.¹⁸ Swallowing side effects typically last an average of about two weeks.¹⁹ Bilateral injections are associated with more breathiness and more swallowing difficulty than unilateral injections, according to a systematic review and meta-analysis.²⁰ Starting with lower doses and titrating upward can help minimize the breathy phase. One comparative study found that starting at a lower bilateral dose produced a significantly shorter duration of breathiness without sacrificing voice outcomes.²¹

When Botulinum Toxin Stops Working

A small number of patients develop resistance to botulinum toxin after years of repeated injections. In a review of 1,400 spasmodic dysphonia patients treated with botulinum toxin type A, only about 0.6 percent became secondarily nonresponsive, a rate considerably lower than what is seen in other dystonias like cervical dystonia, likely because the doses used in the larynx are so much smaller.²² Resistance is driven by the immune system producing antibodies against the toxin. Studies of resistant patients have found significant levels of anti-botulinum toxin antibodies in their blood, while responsive patients had none.²³

The good news is that resistance is not always permanent. After a period of cessation from injections, some patients can resume treatment without recurrence of immunoresistance.²² For patients in whom resistance persists, switching to a different serotype of botulinum toxin or pursuing surgical options becomes the next conversation.

Surgical Options

For patients who want to get off the injection treadmill or who do not respond well to botulinum toxin, two main surgical approaches exist: selective laryngeal adductor denervation-reinnervation (SLAD-R) and type 2 thyroplasty.

SLAD-R works by cutting the nerve branch that drives the overactive adductor muscles and then rerouting a different nerve to reinnervate those muscles, preventing them from wasting away while eliminating the dystonic signal. In the original case series of 21 consecutive patients followed for a median of three years, 19 were judged to have absent to mild dysphonia after the procedure, and only one required further botulinum toxin treatment.²⁴ Longer-term follow-up in a larger group confirmed durable results: voice handicap scores dropped substantially, 83 percent of patients showed significant improvement, and 91 percent reported more fluent speech after surgery. About a quarter still had some voice breaks on evaluation, though most of those were mild.²⁵ Successful reinnervation of the vocal fold adductors by the rerouted nerve has been confirmed in follow-up investigations.²⁶

Type 2 thyroplasty takes a different approach: instead of manipulating the nerve, the surgeon modifies the laryngeal cartilage framework to slightly widen the gap between the vocal folds, reducing the force of their closure. Titanium bridges are often used to hold the cartilage apart. Studies have found significant improvement in voice-related quality of life and acoustic parameters lasting more than two and three years after surgery.²⁷²⁸ Because it is a structural modification rather than a nerve operation, this approach is generally considered more reversible, since the titanium bridge can theoretically be adjusted or removed.

Neither surgery eliminates ADSD in every patient, and both carry a learning curve for the surgeon. The choice between them often depends on the individual patient’s anatomy, symptom pattern, and the expertise available at their treatment center.

Voice Therapy as a Complement

Voice therapy alone does not fix ADSD because the underlying problem is neurological, not behavioral. However, many patients develop compensatory muscular tension on top of their spasms, and voice therapy can address that secondary layer. A study of combined treatment found that patients who received voice therapy after botulinum toxin injection maintained higher airflow rates for longer periods compared to patients who received injections alone. The therapy focused on reducing excessive glottal pressure at the start of voicing and releasing squeezing patterns in the throat. Patients who went through the combined program also showed a carryover effect: when they later received injections without concurrent therapy, their improved vocal habits persisted.²⁹

In practical terms, this means voice therapy is most useful as a complement during the injection cycle, particularly in the first weeks after injection when the vocal folds are temporarily weakened and the patient can more easily retrain their habits. It is not a substitute for the primary treatment, but it can extend the window of good voicing.

The Psychosocial Weight of Living With ADSD

Because the voice is central to identity, work, and social connection, ADSD carries a psychosocial burden that goes well beyond the physical symptom. A controlled questionnaire study found that patients with ADSD had significantly elevated scores on measures of psychological distress, with male patients particularly affected.³⁰ Patients also reported a low sense of control over their condition, which is consistent with the unpredictable nature of the spasms.

The impact on work is measurable. A study of employed ADSD patients found that during their worst voicing periods compared to their best, they reported nearly a 30 percent decrease in work impairment and a similar decrease in overall work productivity. Most of the productivity loss came not from missed days but from reduced effectiveness while on the job.³¹ Despite these difficulties, patients generally did not shift to less vocally demanding occupations, suggesting that the disorder forces people to push through rather than adapt around it.

How ADSD Differs From Abductor Spasmodic Dysphonia

Spasmodic dysphonia exists in two main forms. The adductor type, which accounts for the large majority of cases, involves involuntary closing spasms that squeeze the vocal folds together. The abductor type, which is less common, involves involuntary opening spasms that pull the vocal folds apart, producing intermittent breathy breaks and a whispery quality. Airflow testing has shown measurable differences between the two: patients with ADSD have significantly higher laryngeal resistance than those with abductor spasmodic dysphonia, consistent with the excessive closure in ADSD versus the excessive opening in the abductor form.³² The distinction matters because the treatment targets are different muscles, and the injection sites for botulinum toxin change accordingly.

Emerging Treatments

The fact that many people with ADSD notice their voice symptoms temporarily improve after drinking alcohol has been a longstanding clinical curiosity. Researchers have pursued this lead by testing sodium oxybate, a drug that acts on some of the same brain receptors as alcohol. In an open-label study, alcohol-responsive patients experienced a significant reduction in voice symptoms roughly 30 to 40 minutes after taking the drug, with the effect lasting an average of about three and a half hours.³³ A follow-up survey of patients using sodium oxybate on an as-needed basis over the longer term reported an average reduction in self-perceived voice symptoms of about 79 percent after each dose.³⁴ This is still early-stage research with small numbers of patients, and sodium oxybate carries its own regulatory and safety considerations, but it represents the first credible attempt at an oral medication for ADSD rather than an injected or surgical one.

Another avenue under investigation is repetitive transcranial magnetic stimulation, a non-invasive brain stimulation technique that has shown promise in other forms of dystonia. Researchers are exploring whether stimulating or suppressing specific cortical areas can modulate the abnormal motor circuits responsible for laryngeal spasms.³⁵ This work remains in the exploratory phase, but it reflects a broader shift in the field from treating ADSD only at the muscle level to addressing the brain-circuit dysfunction that drives it.